Novartis

Novartis Foundation and Partners Launch New Hypertension Program in Ghana

Community-based Hypertension Improvement Project (ComHIP) is an innovative healthcare model designed to improve hypertension management and control
Press Release
  • Community-based Hypertension Improvement Project (ComHIP) is an innovative healthcare model designed to improve hypertension management and control
     
  • Screening and treatment is shifted to the community and technology supports healthcare workers and empowers patient self-management
     
  • More than one quarter of the adult population in Ghana has hypertension, but only 4% of these hypertensive patients have it under control
     

Expanding Access to Affordable Treatments Against Chronic Diseases

Novartis Access hosts second stakeholder dialogue
Article

On May 25, Novartis Access held its second stakeholder dialogue in conjunction with the 2016 World Health Assembly to share first learnings from the Kenya launch, and to continue the discussion on how to address the burden of noncommunicable diseases (NCDs) in lower-income countries. This event is part of the company’s public commitment to transparency and open dialogue with stakeholders as Novartis Access is rolled out.

Kenya First Country to Launch ‘Novartis Access’, Expanding Affordable Treatment Options Against Chronic Diseases

Program supports Kenyan government on non-communicable disease (NCD) prevention and control – by 2030, NCDs are expected to cause more than 60% of deaths in the country
Summary: 

•    Novartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and low-middle-income countries
•    Program supports Kenyan government on non-communicable disease (NCD) prevention and control – by 2030, NCDs are expected to cause more than 60% of deaths in the country1
•    Agreements signed with Kenyan government and NGOs include programs to distribute medicines, raise disease awareness and strengthen healthcare system capabilities in key NCDs 

Press Release

•    Novartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and low-middle-income countries
•    Program supports Kenyan government on non-communicable disease (NCD) prevention and control – by 2030, NCDs are expected to cause more than 60% of deaths in the country1
•    Agreements signed with Kenyan government and NGOs include programs to distribute medicines, raise disease awareness and strengthen healthcare system capabilities in key NCDs 

Eradicating Malaria Through Innovation: Where Next After 2015?

To mark the inception of the "European Year of Development" and explore a renewed global health agenda for malaria post-2015, Novartis organized a debate earlier this year in the European Parliament on eradicating malaria through innovation.
Article

To mark the inception of the "European Year of Development" earlier this year, and explore a renewed global health agenda for malaria post-2015, Novartis organized a debate in the European Parliament on eradicating malaria through innovation. Other speakers included representatives from the European Parliament, the European Commission, the Kenya Medical Research Institute and Medicines for Malaria Venture. 

About the Novartis Malaria Initiative

Learn about the disease and what Novartis is doing to contribute to its eradication
Multimedia with summary

Novartis Launches ‘Novartis Access’, a Portfolio of Affordable Medicines to Treat Chronic Diseases in Lower-income Countries

First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer
Summary: 
  • First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer
  • Novartis portfolio to be offered to governments and non-governmental organizations in low- and low-middle-income countries for USD 1 per treatment, per month
  • Some 28 million people die from chronic diseases in low- and middle-income countries each year, representing 75% of such deaths globally1
Press Release
  • First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer
  • Novartis portfolio to be offered to governments and non-governmental organizations in low- and low-middle-income countries for USD 1 per treatment, per month
  • Some 28 million people die from chronic diseases in low- and middle-income countries each year, representing 75% of such deaths globally1

Novartis Foundation Presents Healthcare Models and Disease Elimination Programs at ECTMIH

Novartis and partners will highlight progress towards transforming the health of the poorest populations
Summary: 

Novartis Foundation healthcare models and disease elimination programs showcased at ECTMIH
Telemedicine pilot in rural Ghana demonstrated positive impact and improved primary health services as reported by nurses, midwives and patients

  • Retrospective contact tracing of former leprosy patients in Cambodia was effective in reducing disability of new patients through earlier diagnosis
  • Electronic supportive supervision of healthcare professionals in Tanzania helped to identify major quality gaps and showed quick improvements in skills
  • First mobile phone-facilitated leprosy detection system helps identify patients in remote areas of the Philippines
Press Release

Novartis Foundation healthcare models and disease elimination programs showcased at ECTMIH
Telemedicine pilot in rural Ghana demonstrated positive impact and improved primary health services as reported by nurses, midwives and patients

  • Retrospective contact tracing of former leprosy patients in Cambodia was effective in reducing disability of new patients through earlier diagnosis
  • Electronic supportive supervision of healthcare professionals in Tanzania helped to identify major quality gaps and showed quick improvements in skills
  • First mobile phone-facilitated leprosy detection system helps identify patients in remote areas of the Philippines

Photos: Novartis 12th Annual International BioCamp

Photos of attendees and winners of Novartis BioCamp
Multimedia with summary

Today, Novartis announced the winners of its twelfth annual International Biotechnology Leadership Camp (BioCamp), a three-day seminar bringing biotechnology and business experts together with 70 selected students from leading international universities in 24 countries and territories, originating from 31 different nations.

Novartis Continues Commitment to go the Last Mile in Effort to Eliminate Leprosy

New five-year commitment includes donation of treatments worth more than USD 40 million and is expected to reach an estimated 1.3 million patients
Summary: 

Novartis continues commitment to go the last mile in effort to eliminate leprosy

  • New five-year commitment includes donation of treatments worth more than USD 40 million and is expected to reach an estimated 1.3 million patients
     
  • Novartis Foundation’s new leprosy contact tracing program now launched in five countries
     
  • The company and foundation have a strong legacy in the fight against leprosy, donating medicines and developing programs to improve care of patients
Press Release

Novartis continues commitment to go the last mile in effort to eliminate leprosy

  • New five-year commitment includes donation of treatments worth more than USD 40 million and is expected to reach an estimated 1.3 million patients
     
  • Novartis Foundation’s new leprosy contact tracing program now launched in five countries
     
  • The company and foundation have a strong legacy in the fight against leprosy, donating medicines and developing programs to improve care of patients

Novartis Announces Winners of its 12th Annual International Biotechnology Leadership Camp (BioCamp)

Novartis BioCamp engages students around scientific advances and entrepreneurial opportunities
Summary: 

Novartis International BioCamp highlights how collaboration and diversity drive innovation and inspires future science leaders

  • The International Biotechnology Leadership Camp (BioCamp) engages students around scientific advances and entrepreneurial opportunities
  • The interactive program brought 70 university students from 24 countries and territories to Novartis headquarters in Basel, Switzerland
    • Elena Gross, Sarmishtha Sharma and Masatoshi Takara are the winners of the case study competition
  • Novartis cultivates an inclusive high-performance environment encouraging collaboration by championing high performing teams with diversity and inclusion
Press Release

Novartis International BioCamp highlights how collaboration and diversity drive innovation and inspires future science leaders

  • The International Biotechnology Leadership Camp (BioCamp) engages students around scientific advances and entrepreneurial opportunities
  • The interactive program brought 70 university students from 24 countries and territories to Novartis headquarters in Basel, Switzerland
    • Elena Gross, Sarmishtha Sharma and Masatoshi Takara are the winners of the case study competition
  • Novartis cultivates an inclusive high-performance environment encouraging collaboration by championing high performing teams with diversity and inclusion

Pages

Subscribe to Novartis